Fibroid Removal — Cost, Top Hospitals & Success Rates | MyMedicPlus

Uterine fibroids (leiomyomas or myomas) are the most common benign tumours of the female reproductive tract — affecting up to 70% of women by age 50, though only 25–30% are symptomatic. They are smooth muscle tumours arising from the uterine myometrium, driven by oestrogen and progesterone, and characteristically regress after menopause. Fibroids are classified by location: submucosal (protruding into the uterine cavity — most strongly associated with heavy menstrual bleeding, subfertility, and pregnancy loss); intramural (within the myometrium — most common; causes uterine enlargement and heavy bleeding when large); and subserosal (projecting from the outer uterine surface — may be pedunculated; causes pressure symptoms when large).

Fibroid symptoms include: heavy menstrual bleeding (HMB — the most common symptom; can cause iron deficiency anaemia); dysmenorrhoea (painful periods); pelvic pressure or pain; urinary frequency/urgency (anterior fibroids compressing the bladder); constipation (posterior fibroids); subfertility and recurrent miscarriage (submucosal fibroids); and occasionally acute pain from fibroid degeneration (red degeneration, particularly in pregnancy, or torsion of pedunculated fibroids).

Not all fibroids require treatment — management decisions are based on symptom severity, fibroid characteristics (size, number, location), reproductive goals, and patient preference. Options range from watchful waiting (asymptomatic fibroids), medical therapy (tranexamic acid, hormonal management, GnRH antagonists such as relugolix or ulipristal acetate), minimally invasive procedures (UFE, HIFU, endometrial ablation), to surgical removal (myomectomy — uterine-preserving; hysterectomy — definitive). Fertility preservation is a critical consideration in all treatment decisions for premenopausal women.

• Heavy menstrual bleeding (HMB) from fibroids: The most common fibroid complication — blood loss >80 mL per cycle. Treated medically (tranexamic acid, NSAIDs, progestogens, combined OCP, LNG-IUS — Mirena reduces HMB by 90%); procedurally (endometrial ablation — appropriate for women who have completed their family; UFE); or surgically (myomectomy; hysterectomy). Oral GnRH antagonist combination therapy (relugolix 40 mg + oestradiol 1 mg + norethisterone 0.5 mg — LIBERTY trials): significantly reduces heavy bleeding and fibroid volume; approved FDA 2021 and EMA 2022 for up to 24 months. Iron deficiency anaemia from HMB requires treatment with ferrous sulphate; severe anaemia may require IV iron infusion or pre-operative GnRH agonist to correct anaemia before surgery.
• Submucosal fibroids (FIGO type 0, 1, 2) — subfertility and pregnancy loss: Submucosal fibroids distort the uterine cavity, impairing embryo implantation and increasing miscarriage risk. Hysteroscopic myomectomy (surgical removal through the cervix without incision) is the gold standard treatment — significantly improves implantation rates and live birth rates (ORR approximately 2× improvement in RCTs). NICE recommends hysteroscopic myomectomy for submucosal fibroids before IVF. Recovery: 1–2 days; no abdominal incision; most women return to work within 1 week.
• Large or multiple intramural fibroids (FIGO type 3–6): For fertility-preserving treatment: laparoscopic or open myomectomy (abdominal myomectomy). Laparoscopic myomectomy: equivalent oncological and fertility outcomes to open myomectomy (RCTs confirming equivalent pregnancy rates); faster recovery (3–5 days in hospital vs. 4–7 days); less blood loss; less pain. Open (abdominal) myomectomy: necessary when very large (>10 cm) or very numerous (>5–6) fibroids are present. Robotic-assisted laparoscopic myomectomy available at specialist centres — comparable outcomes with potential advantages for uterine suture reconstruction.
• Symptomatic fibroids in women who have completed their family: Uterine fibroid embolisation (UFE): interventional radiology procedure (bilateral uterine artery embolisation) — polyvinyl alcohol particles or microspheres block fibroid blood supply, causing ischaemic necrosis. 85% symptom improvement at 2 years; fibroid volume reduction 40–60%. Outpatient or 1-day procedure; 2-week recovery. Contraindicated if uterine cancer not excluded, significant uterine infection, or renal impairment. Not recommended if planning future pregnancy (limited evidence for uterine rupture risk in subsequent pregnancy). MRI-guided focused ultrasound (HIFU): non-invasive ultrasound energy focused to ablate fibroid tissue through intact skin; day-case procedure; 75–85% symptom improvement at 2 years. Hysterectomy: definitive cure — no recurrence possible. Options: laparoscopic, laparoscopic-assisted vaginal (LAVH), total laparoscopic, or abdominal hysterectomy depending on uterine size, surgical expertise, and patient factors.

Surgical myomectomy eligibility:

• Symptomatic fibroids (heavy bleeding causing anaemia, pressure symptoms, pain, subfertility) with desire to preserve the uterus and/or future fertility
• Submucosal fibroids (FIGO 0–2): hysteroscopic myomectomy. Intramural and subserosal fibroids: laparoscopic or open myomectomy based on size, number, and accessibility
• Laparoscopic myomectomy: fibroids up to 8–10 cm, ideally <3–5 fibroids; adequate uterine access on laparoscopy; surgeon with advanced laparoscopic skills and adequate volume
• Pre-operative GnRH agonist (leuprorelin 3–6 months) or GnRH antagonist (relugolix): reduces fibroid size by 25–40% and corrects anaemia before surgery — consider for large fibroids or significant anaemia
• Pre-operative MRI mapping: defines fibroid number, size, location (FIGO classification), relationship to cavity and endometrium — essential surgical planning tool, particularly before laparoscopic myomectomy

UFE eligibility:

• Premenopausal women with symptomatic fibroids who have completed childbearing or do not plan future pregnancy
• Uterine malignancy excluded (MRI + endometrial biopsy if indicated)
• Adequate renal function (contrast nephropathy risk with iodinated contrast)
• No active uterine or pelvic infection
• Pedunculated subserosal fibroids (long stalk): relative contraindication — risk of stalk necrosis and peritonitis post-UFE

Management of Fibroid Removal is individualised based on disease severity, patient age, comorbidities, and patient values. The gynaecological team develops a personalised plan incorporating the following evidence-based treatment modalities:

• Conservative and lifestyle-based management: For many presentations, targeted lifestyle modification — including nutritional optimisation, graded physical activity, weight management, alcohol and smoking cessation — forms the foundation of care. Regular specialist monitoring and patient self-management education enable early detection of deterioration and empower patients to actively participate in their treatment.
• Pharmacological therapy: Evidence-based drug therapy tailored to disease mechanism and individual patient profile forms the pharmacological backbone. First-line agents are selected per current international guidelines, with treatment escalated to second-line or combination therapy for inadequate responders. Regular monitoring ensures therapeutic efficacy and detects adverse effects early.
• Procedural and interventional approaches: Where pharmacological management is insufficient or specific structural or functional abnormalities are identified, minimally invasive or interventional procedures are considered. These are performed by experienced gynaecological specialists at accredited facilities with appropriate pre-procedure preparation and post-procedure monitoring protocols.
• Surgical treatment: Surgery is indicated for patients with advanced disease, complications, or conditions unresponsive to medical management. Modern surgical approaches include laparoscopic, robotic-assisted, and image-guided techniques that minimise operative morbidity and accelerate recovery. Surgical decisions are made following multidisciplinary discussion and informed consent.
• Multidisciplinary team (MDT) care: Complex presentations are managed through an MDT integrating expertise from relevant specialties — gynaecological medicine, radiology, physiotherapy, nutrition, psychology, and palliative care as appropriate. MDT-driven care demonstrably improves outcomes for complex conditions. Patient and family involvement in MDT planning ensures alignment with individual values.
• Emerging and clinical trial options: Access to investigational treatments through clinical trials at specialist centres offers patients with refractory or high-risk presentations the opportunity to access next-generation therapies under systematic monitoring. Trial eligibility is assessed as part of the MDT plan.

• Hysteroscopic myomectomy — dramatic improvement in HMB and fertility: Complete resection of type 0–1 submucosal fibroids achieves 75–90% reduction in heavy menstrual bleeding — often normalising periods to acceptable levels without further treatment. Fertility improvement: implantation rates increase from approximately 30% to 55% after hysteroscopic myomectomy for infertile women with submucosal fibroids. Live birth rates improve significantly — critical for IVF success. Day-case procedure with minimal recovery time — one of the most rewarding surgical interventions in gynaecology.
• Laparoscopic myomectomy — fertility preservation with rapid recovery: Achieves 70–85% improvement in HMB, pressure symptoms, and dysmenorrhoea. Pregnancy rates after laparoscopic myomectomy: cumulative 12-month pregnancy rate 50–60% in fertility-seeking patients. Comparable pregnancy rates and delivery outcomes to open myomectomy in RCTs. Hospital stay 2–3 days; return to work 2–3 weeks (vs. 4–6 weeks for open myomectomy). Laparoscopic myomectomy is the gold standard approach for fertility-preserving intramural fibroid removal when technically feasible.
• UFE — high efficacy without surgery: Randomised trials (REST, EMMY) demonstrate UFE and hysterectomy achieve equivalent quality-of-life improvements and patient satisfaction at 2 years — with UFE providing this benefit without surgery, general anaesthesia, or hysterectomy. 85% symptom improvement; fibroid volume reduction 40–60%; uterus preserved. Recovery 2 weeks vs. 4–6 weeks for open surgery. Cost-effective and increasingly available. Suitable for women who refuse surgery, have anaesthetic risk, or prefer uterine preservation without myomectomy.
• Relugolix combination therapy — oral medical management: Relugolix 40 mg + oestradiol 1 mg + norethisterone 0.5 mg (Ryeqo in Europe; Myfembree in USA): reduces HMB in 72–74% of women vs. 17–19% placebo (LIBERTY 1 and 2 trials); reduces fibroid volume 30–40%; oral daily tablet; well tolerated; approved for up to 24 months. Provides a non-surgical, non-injectable option for women who wish to delay or avoid surgery — particularly useful for perimenopausal women approaching natural menopause and fibroid regression.

• Recurrence after myomectomy: The most important long-term limitation of myomectomy — approximately 25–30% of women require further surgical intervention within 5 years (reoperation or hysterectomy) due to symptomatic fibroid recurrence. Risk factors for recurrence: young age at surgery, multiple fibroids at first surgery, large number of fibroids (if all could not be removed). Post-operative GnRH analogue or progestogen to delay recurrence may be used. Women should be counselled that myomectomy controls symptoms but does not permanently cure the predisposition to fibroid development.
• Surgical risks — myomectomy: Blood loss: myomectomy is associated with significant haemorrhage risk — average blood loss 200–500 mL; transfusion required in 2–5% (open) and 1–2% (laparoscopic). Vasopressin injection into fibroid pedicles and tourniquet techniques reduce blood loss. Cell saver autologous blood retrieval for large open myomectomy. Conversion from laparoscopic to open: 1–5% depending on fibroid characteristics and surgeon experience. Adhesion formation: potentially impairing future fertility or causing bowel obstruction. Uterine rupture in subsequent pregnancy (rare, <1%, but most severe complication) — particularly if myometrium was opened deeply during surgery; most surgeons recommend caesarean section delivery after open myomectomy or multiple laparoscopic myomectomy.
• UFE-specific risks: Post-embolisation syndrome: fever, pelvic pain, nausea within 24–72 hours of procedure — managed with NSAIDs and antiemetics; resolves within 1 week. Fibroid passage: submucosal fibroids may be expelled vaginally 2–6 weeks post-UFE — uncomfortable but usually manageable. Premature menopause: 1–2% in women under 40 (ovarian embolisation from inadvertent contrast into ovarian vessels). Infection: rare but serious — fibroid abscess and uterine sepsis requiring hysterectomy. Fertility after UFE: limited but emerging data suggest pregnancy is possible post-UFE; however, UFE is not currently recommended for women specifically wishing future pregnancy due to incomplete safety evidence.
• Hysteroscopic myomectomy risks: Uterine perforation (0.5–1%); fluid overload (absorption of distension medium, particularly with monopolar resection — glycine fluid; use bipolar or normal saline-based systems reduces risk); cervical laceration; incomplete resection (type 1–2 fibroids often require planned second hysteroscopy). Thermal injury to surrounding endometrium with ablation techniques — may reduce fertility.

Immediate post-operative monitoring: Following Fibroid Removal, patients are monitored in the recovery unit for vital signs, wound integrity, pain control, and early complications. Discharge planning begins on the day of surgery; patients leave with written instructions covering wound care, activity restrictions, medication schedule, diet, and warning signs requiring prompt review.

Short-term follow-up (2–8 weeks): A post-operative review at 2–4 weeks assesses wound healing, functional recovery, and histology results where applicable. Medications are reviewed; physiotherapy is initiated. Return-to-work and activity timelines are confirmed based on individual recovery progress.

Long-term surveillance: Regular specialist follow-up — every 3–6 months in the first year, then annually — monitors for recurrence, late complications, and related health parameters. Imaging and laboratory surveillance are conducted at clinically indicated intervals. Patients are educated to report new or worsening symptoms promptly between scheduled appointments.

Fibroid treatment costs vary considerably by procedure type and country. India offers world-class minimally invasive fibroid surgery at significantly lower cost:

• India: Gynaecologist consultation and USS fibroid assessment: USD 30–100. Hysteroscopic myomectomy: USD 600–2,000 (day case). Laparoscopic myomectomy: USD 1,000–3,500. Open (abdominal) myomectomy: USD 1,500–4,000. Robotic-assisted myomectomy: USD 3,000–7,000. UFE (uterine fibroid embolisation): USD 1,500–4,000. MRI pelvis: USD 80–200. Relugolix (Ryeqo generic — not yet widely available in India; leuprorelin depot 3.75 mg/month generic): USD 30–60/injection. Tranexamic acid and NSAIDs: minimal cost. Leading centres: Apollo Hospitals, Fortis, Cloudnine, Rainbow Children's Hospital, AIIMS. India's minimally invasive gynaecology units perform high volumes of laparoscopic and hysteroscopic fibroid surgery with internationally trained surgeons.
• Thailand: Laparoscopic myomectomy: USD 4,000–10,000. UFE: USD 3,000–7,000 at Bangkok international hospitals. MRI: USD 300–600.
• United Kingdom (NHS): Medical therapy (tranexamic acid, LNG-IUS, GnRH analogues) free on NHS prescription. Hysteroscopic and laparoscopic myomectomy available on NHS — waiting times 6–12 months. UFE commissioned by NHS England — available at designated interventional radiology centres. Hysterectomy for definitive treatment available on NHS. Private sector: laparoscopic myomectomy GBP 5,000–12,000.
• United States: Laparoscopic myomectomy: USD 12,000–30,000 (facility + surgeon + anaesthesia). Robotic myomectomy: USD 15,000–40,000. Open myomectomy: USD 15,000–35,000. UFE: USD 10,000–20,000. Relugolix (Myfembree): USD 800–1,000/month. Hysterectomy: USD 15,000–40,000.

Alternative or complementary approaches may be considered for patients unsuitable for standard Fibroid Removal, preferring less intensive treatment, or seeking additional options alongside conventional care:

• Watchful waiting / active surveillance: For patients with mild or stable presentations, a period of active monitoring with regular specialist review may defer treatment. This approach is appropriate only when disease trajectory is slow and quality of life is maintained, with clear pre-defined triggers for initiating active treatment.
• Evidence-based complementary approaches: Structured exercise programmes, dietary interventions, mindfulness-based stress reduction, sleep optimisation, and physiotherapy may complement conventional treatment or provide symptomatic benefit. All complementary approaches should be discussed with the treating specialist to ensure no interactions with ongoing treatments.
• Alternative specialist or second opinion: Patients who have not responded to initial treatment may benefit from referral to a specialist with higher subspecialty expertise or a tertiary centre with access to advanced techniques and clinical trials. A formal second opinion from an experienced specialist is always appropriate before major treatment decisions.
• Clinical trial participation: For refractory or advanced presentations, clinical trials at specialist centres offer access to investigational therapies not yet in routine use — including novel pharmacological agents, targeted biologics, and innovative procedures. Trial costs for experimental components are typically borne by the sponsor.
• Palliative and supportive care: When curative or disease-modifying treatment is not appropriate or desired, specialist palliative care maximises quality of life through expert symptom control, psychological and spiritual support, and coordinated care. Modern palliative medicine can be delivered alongside active treatment at any disease stage and consistently improves patient wellbeing.